These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 18394765)

  • 1. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
    Wijesinghe PR; Abeysinghe MR; Yoksan S; Yao Y; Zhou B; Zhang L; Yaich M; Neuzil KM; Victor JC
    Vaccine; 2014 Aug; 32(37):4751-7. PubMed ID: 24951871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
    Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
    Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
    Nkrumah FK; Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA
    Bull World Health Organ; 1998; 76(4):353-9. PubMed ID: 9803586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
    Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
    J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.
    Torresi J; McCarthy K; Feroldi E; Méric C
    Vaccine; 2010 Nov; 28(50):7993-8000. PubMed ID: 20934459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
    Huang LM; Lin TY; Chiu CH; Chiu NC; Chen PY; Yeh SJ; Boaz M; Hutagalung Y; Bouckenooghe A; Feroldi E
    Vaccine; 2014 Sep; 32(41):5363-9. PubMed ID: 24631095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
    Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
    Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of Abhay M and M-vac vaccines in healthy infants: a phase III multicentric randomized single blind trial.
    Zodpey SP; Agarkhedkar SR; Reddy GA; Rao MI; Shenoy UV; Murthy SR; Maiya PP
    Indian J Public Health; 2008; 52(1):5-10. PubMed ID: 18700714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
    Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
    Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine].
    Ma FB; Zheng L; Bi C; Tao H; Zhou YL; Zhang JL; Tang FY; Xie P; Zheng CZ; Peng WB; Jiang RJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):113-5. PubMed ID: 12697111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody.
    Premenko-Lanier M; Rota PA; Rhodes GH; Bellini WJ; McChesney MB
    J Infect Dis; 2004 Jun; 189(11):2064-71. PubMed ID: 15143474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
    Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.